Advisor OS LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 613 shares of the company’s stock, valued at approximately $202,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Public Employees Retirement Association of Colorado raised its stake in shares of IDEXX Laboratories by 3.7% in the 1st quarter. Public Employees Retirement Association of Colorado now owns 12,378 shares of the company’s stock valued at $2,998,000 after purchasing an additional 446 shares during the period. D.A. Davidson & CO. lifted its stake in IDEXX Laboratories by 4.5% in the 1st quarter. D.A. Davidson & CO. now owns 1,166 shares of the company’s stock valued at $282,000 after acquiring an additional 50 shares in the last quarter. AE Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 320.7% during the 1st quarter. AE Wealth Management LLC now owns 4,762 shares of the company’s stock worth $1,154,000 after acquiring an additional 3,630 shares in the last quarter. Bartlett & Co. LLC acquired a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $107,000. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of IDEXX Laboratories by 709.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 19,910 shares of the company’s stock worth $4,823,000 after purchasing an additional 17,451 shares in the last quarter. 87.01% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Credit Suisse Group increased their price objective on shares of IDEXX Laboratories from $415.00 to $422.00 and gave the stock an “outperform” rating in a research note on Monday, August 17th. Bank of America upped their price objective on IDEXX Laboratories from $300.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $280.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, BidaskClub cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 14th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $357.40.

Shares of NASDAQ:IDXX traded down $7.03 on Wednesday, hitting $362.21. The company had a trading volume of 16,576 shares, compared to its average volume of 573,173. The stock has a market cap of $31.41 billion, a price-to-earnings ratio of 68.35, a P/E/G ratio of 4.20 and a beta of 0.81. The stock has a 50 day moving average price of $380.60 and a 200 day moving average price of $309.72. IDEXX Laboratories, Inc. has a 1-year low of $168.65 and a 1-year high of $407.86. The company has a current ratio of 1.44, a quick ratio of 1.02 and a debt-to-equity ratio of 3.29.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, July 31st. The company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.17 by $0.55. The business had revenue of $637.20 million during the quarter, compared to the consensus estimate of $589.98 million. IDEXX Laboratories had a net margin of 18.59% and a return on equity of 241.52%. IDEXX Laboratories’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.43 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 5.66 earnings per share for the current fiscal year.

In other news, CFO Brian P. Mckeon sold 83,724 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $378.97, for a total value of $31,728,884.28. Following the completion of the sale, the chief financial officer now directly owns 58,386 shares in the company, valued at $22,126,542.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Giovani Twigge sold 7,316 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $388.19, for a total value of $2,839,998.04. Following the completion of the sale, the vice president now owns 14,222 shares of the company’s stock, valued at $5,520,838.18. The disclosure for this sale can be found here. Insiders sold 122,316 shares of company stock worth $46,594,823 in the last ninety days. 2.53% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: What is included in the gross domestic product?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.